Previous 10 | Next 10 |
Exelixis (EXEL): Q3 Non-GAAP EPS of $0.04 beats by $0.03; GAAP EPS of -$0.10 misses by $0.11.Revenue of $231.09M (-14.9% Y/Y) beats by $15.69M.“In the third quarter of 2020, the Exelixis team built the foundation to accelerate revenue growth with CABOMETYX® (cabozantinib) in ...
- Total Revenues of $231.1 Million, Cabozantinib Franchise Revenues of $168.6 Million - - GAAP Diluted EPS of $(0.10), Non-GAAP Diluted EPS of $0.04 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) toda...
[[AAXN]], [[ACLS]], [[ADT]], [[AGO]], [[AIG]], [[AINV]], [[ALRM]], [[ALTR]], [[AMCR]], [[AMH]], [[AMN]], [[ANGI]], [[APPN]], [[ATGE]], [[ATRC]], [[AVLR]], [[AYX]], [[AZPN]], [[BFAM]], [[BGS]], [[BHF]], [[BIGC]], [[BILL]], [[BKNG]], [[BLDP]], [[BMRN]], [[BNFT]], [[CABO]], [[CARG]], [[CDAY]], [...
Michelin , the tire company, makes tires. There is no Wall Street talk of the company's tangential markets, optionality, or subscription-based platforms. It just sells tires. And it sells them for every kind of vehicle, from bicycles to earth movers to airplanes. Exelixis (NAS...
– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in November: Credit...
Comparing Illumina (NASDAQ: ILMN) with Exelixis (NASDAQ: EXEL) feels like a mismatch. The former is a dominant provider of genome sequencers serving as -- some might argue -- the foundation for the future of medicine. The latter is a scrappy biotech stock that has found ways...
Cabometyx/Opdivo combination data in first-line renal cell carcinoma succeeded in its pivotal trial and achieved FDA approval, but figures to accomplish little for both companies. Analysts point to the stronghold Opdivo and Yervoy have within the first-line indication and the lack of ...
Exelixis' (EXEL) partner Takeda Pharmaceutical (TAK) and Ono Pharmaceutical have submitted a supplemental application in Japan for manufacturing and marketing approval of CABOMETYX in combination with OPDIVO (nivolumab) for the treatment of patients with unresectable, advanced or metastatic r...
– Submission based on the CheckMate -9ER phase 3 pivotal trial, which showed CABOMETYX in combination with OPDIVO improved overall survival and doubled median progression-free survival and objective response rate versus sunitinib – Exelixis, Inc. (NASDA...
Exelixis (EXEL) has enrolled the first patient into the dose-escalation cohort of the combination arm of the Phase 1 trial evaluating XL092 alone and in combination with Genentech's atezolizumab (TECENTRIQ) in patients with advanced solid tumors.Initiated in February 2019, the dose-esca...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...